Expression of c-myc and c-fos and binding sites for estradiol and progesterone in human pituitary tumors.
We studied the concentration of mRNA from the oncogenes c-myc and c-fos in human pituitary adenomas by Northern blot hybridization (35 somatotrophinomas, 9 prolactinomas, 21 nonsecreting and 3 adrenocorticotrophinomas). The concentration of estrogens and progesterone receptors was also investigated. The levels of c-myc and c-fos mRNA was higher in nonsecreting tumors which were generally the largest and had a higher percentage of recurrence after surgery than the other groups. High concentration of estrogen receptors was observed in tumors derived from cells which are normally the target of this hormone, mainly prolactinomas. They were also present in somatotrophic and nonsecreting adenomas, related to the presence of prolactin or gonadotrophin cells in these tumors. The presence of estrogen receptors indicates that the tumor cells maintain their differentiation and a good prognosis as is the case for prolactinomas. We did not find any relationship between estrogen receptors and the concentration of c-myc and c-fos oncogenes. Larger adenomas (mainly nonsecreting) had higher levels of c-myc and c-fos mRNA than the other tumors and they had an important percentage of recurrence after surgery. It is clear that tumor size is related to the outcome after surgery and that nonsecreting adenomas are usually large because of the late diagnosis. However two large somatotrophinomas with extrasellar expansion also had overexpression of both oncogenes and both relapsed after surgery.
Machiavelli
G A
GA
Departamento de Endocrinología, Centro de Investigaciones Médicas Albert Einstein, Fundación CIMAE, Capital Federal, Argentina.
Rivolta
C M
CM
Artese
R
R
Basso
A
A
Burdman
J A
JA
D000236:Adenoma / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D004958:Estradiol / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D010911:Pituitary Neoplasms / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D011374:Progesterone / Q000378:metabolism*; D011379:Prognosis; D015175:Prolactinoma / Q000235:genetics / Q000378:metabolism; D011485:Protein Binding / Q000502:physiology; D016760:Proto-Oncogene Proteins c-fos / Q000235:genetics* / Q000378:metabolism; D016271:Proto-Oncogene Proteins c-myc / Q000235:genetics* / Q000378:metabolism; D012333:RNA, Messenger / Q000032:analysis; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D016760:Proto-Oncogene Proteins c-fos; D016271:Proto-Oncogene Proteins c-myc; D012333:RNA, Messenger; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D011374:Progesterone; D004958:Estradiol